Alterity Therapeutics Limited
PRNAF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.09 | -0.78 | 0.07 |
| FCF Yield | -39.27% | -79.38% | -24.67% | -33.96% |
| EV / EBITDA | 0.26 | -0.17 | -4.50 | -0.12 |
| Quality | ||||
| ROIC | -34.44% | -140.78% | -63.87% | -43.78% |
| Gross Margin | 97.66% | 94.67% | 97.39% | 98.94% |
| Cash Conversion Ratio | 0.94 | 0.66 | 1.45 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.57% | -7.77% | -3.36% | – |
| Free Cash Flow Growth | 9.20% | 37.08% | -61.30% | 28.31% |
| Safety | ||||
| Net Debt / EBITDA | 2.26 | 0.64 | 1.07 | 2.24 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.04 | 0.03 |
| Cash Conversion Cycle | -1,276.42 | -624.79 | 3,852.00 | -6,807.10 |